Amylin submits metreleptin rolling submission BLA for treatment of rare types of lipodystrophy Amylin Pharmaceuticals, Inc . today announced that it has submitted the initial parts of a rolling submission for a Biologics Permit Application to the U.S. Food and Medication Administration for the use of metreleptin to take care of diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy. Consistent with the severity and rare nature of the disorder, Amylin offers received both orphan drug designation from FDA’s Workplace of Orphan Products Development, in addition to Fast Monitor designation for the use of metreleptin in patients with lipodystrophy.